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SUMMARY
Objective: To evaluate serum concentrations of CA-125 and soluble CD-23 and to cor-
relate them with clinical symptoms, localization and stage of pelvic endometriosis and 
histological classification of the disease. Methods: Blood samples were collected from 
44 women with endometriosis and 58 without endometriosis, during the first three days 
(1st sample) and during the 7th, 8th and 9th day (2nd sample) of the menstrual cycle. 
Measurements of CA-125 and soluble CD-23 were performed by ELISA. Mann-Whitney 
U test was used for age, pain evaluations (visual analog scale) and biomarkers concen-
trations. Results: Serum levels of CA-125 were higher in endometriosis patients when 
compared to the control group during both periods of the menstrual cycle evaluated in 
the study. This marker was also elevated in women with chronic pelvic pain, deep dys-
pareunia (2nd sample), dysmenorrhea (both samples) and painful defecation during the 
menstrual flow (2nd sample). CA-125 concentration was higher in advanced stages of 
the disease in both samples and also in women with ovarian endometrioma. Concerning 
CD-23, no statistically significant differences were observed between groups. Conclu-
sion: The concentrations of CA-125 were higher in patients with endometriosis than 
in patients without the disease. No significantly differences were observed for soluble 
CD-23 levels between groups.
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INTRODUCTION
The most accurate procedure for diagnosis of endo-
metriosis is laparoscopy, an invasive surgical method. 
The definitive diagnosis is based on the visualization of the 
characteristic lesions and on histological confirmation. 
The identification of less invasive and more accessible 
markers of the disease is suitable. Several studies have 
reported that CA-125, a glycoprotein of epithelial origin 
found in normal cells, has high serum concentrations in 
patients with endometriosis, mainly when evaluated dur-
ing the menstrual flow1-3.
Another biomarker of interest to this study was sol-
uble CD-23, a protein that is expressed on the surface of 
cell membrane, commonly identified as the low a nity 
IgE receptor on B cells, eosinophils, monocytes, dendritic 
cells, epithelial Langerhans cells and platelets4.
Based on the evidence of increased concentrations of 
soluble CD-23 in peritoneal fluid of women with endo-
metriosis, it was suggested that the disease would acti-
vate B cells, which would promote the release of higher 
concentrations of soluble CD-235,6. This hypothesis was 
strengthened by the identification that women treated 
with danazol had a greater reduction in the concentration 
of CD-23 when compared to patients treated with leupro-
lide acetate. If danazol could suppress humoral and cell-
mediated immune responses and could alter macrophage 
function, by a significant increase of soluble leukocyte an-
tigen class I and class II (HLA-I and HLA-II), due to the 
release of these antigens from intracellular stores, it could 
also promote the reduction of inflammatory process in 
endometriosis. It would activate anti-inflammatory cyto-
kines, similar to what occurs in normal pregnancy, creat-
ing an inhospitable environment for the establishment of 
ectopic endometrium. Based on these arguments, it was 
suggested that changes in the levels of HLA by danazol 
may reflect the immune competence and the function 
of macrophages in endometriosis7,8. Thus, the hypoth-
esis stated by Odukoya et al.9 has reinforced that soluble 
CD-23 may be involved in the development and mainte-
nance of endometriosis and may serve as a possible bio-
logical marker.
The presence of soluble CD-23 in patients with endo-
metriosis could occur because the endometrial cells that, 
by reflux, reach the peritoneal cavity are presented by 
macrophages and other antigen presenting cells to CD4+ 
T cells that become activated by cytokines, as IL-4 and IL-
10. Recently, our group reported that these cytokines are 
increased in patients with endometriosis and promote the 
release of CD-23 by B cells and monocytes10. Thus, CD-23 
concentration could also be elevated as a consequence of 
increased concentration of cytokines.
The aim of this study was to determine serum concen-
trations of CA-125 and soluble CD-23 in patients with and 
without endometriosis, in two phases of the menstrual 
cycle: 1st, 2nd or 3th day and 8th, 9th or 10th day. We also 
compared the concentrations of CA-125 and CD-23 with 
clinical symptoms, stage and site of the lesions and histo-
logical classification of the disease.
METHODS 
PATIENTS 
This study was approved by the Ethics in Research Com-
mittee of Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo. From June 2007 to Oc-
tober 2010, the following inclusion criteria were applied 
to 1,920 consecutive patients complaining of infertility, 
pelvic pain or desire for family planning by tubal ligation: 
age between 18 and 45 years, absence of hormone therapy 
within three months prior to consultation, absence of au-
toimmune diseases confirmed by history and laboratory 
tests, when necessary; evidence of ovarian function and 
laparoscopy examination for the investigation of infertil-
ity or pelvic pain refractory to clinical therapy, based on 
complaints and on gynecological examination or imag-
ing findings, consistent with endometriosis. 
One hundred and four patients met inclusion criteria 
and were invited to participate in the study, aã er having 
been informed about the research objectives. Patients 
underwent medical history, to investigate the presence 
of six symptoms most commonly associated with endo-
metriosis: dysmenorrheal, chronic pelvic pain, deep dys-
pareunia, infertility, bowel and urinary cyclic symptoms. 
The intensity of chronic pelvic pain and dyspareunia was 
evaluated using a visual analogue scale of 10 points. Pel-
vic examination was the next step, searching for retro-
uterine nodules, thickening of the uterosacral ligament 
or pelvic masses. Patients with endometriosis clinical 
suspicion was submitted to pelvic and transvaginal ultra-
sound and, when necessary, to pelvic MRI. Laparoscopy 
was indicated in the presence of pain even aã er clinical 
treatment or if the image exams showed ovarian endome-
trioma and/or deep infiltrative lesions affecting retrocer-
vical region, vagina, bowel, bladder or ureter.
Up to three months before laparoscopy, aã er eight 
hours fasting, all patients had a venipuncture to col-
lect 5 mL of blood sample that was stored in a dry tube. 
The first sampling occurred between the 1st, 2nd or 3th day 
of the menstrual cycle and the second at the 8th, 9th or 
10th day. The samples were sent to a freezer, maintained at 
–20° C, at the laboratory and the analysis was performed 
aã er the collection of all samples. 
Aã er laparoscopy, patients were divided into two 
groups: the first (case group) consisted of 45 patients with 
a diagnosis of endometriosis confirmed by pathological 
examination. The second (control group) consisted of 59 
women without endometriosis. One patient in the case 
group and another in the control group leã  the research. 
Thus, the case group was composed of 44 patients and the 
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control group, of 58 patients. In the case group, the dis-
ease was classified according to American Society for Re-
productive Medicine11 stages and location of the disease. 
In the histological analysis of excised tissues, we followed 
the classification pattern proposed by Abrão et al.12.
LABORATORY ANALYSIS
The determination of serum CA-125 levels was per-
formed using a sandwich technique of a commercial ELI-
SA kit (Elecsys®, Roche — NY, USA) and the dosage of 
serum soluble CD-23 was also performed with a ELISA 
kit (Bender MedSystems, Vienna, Austria) according to 
manufacturers instructions. The analyte range of CA-125 
and soluble CD-23 is 25-35 IU/mL and 10-91 U/mL, re-
spectively.
STATISTICAL ANALYSIS 
Statistical analysis was performed to compare Ca-125 
and CD-23 concentrations with case and control groups 
regarding the presence and intensity of clinical com-
plaints related to endometriosis, site of disease, staging 
according to the ASRM and histopathological analysis. 
We compared means using a Mann-Whitney U test, with 
5% significance level. 
RESULTS
We found that CA-125 average concentrations were sig-
nificantly higher in cases when compared to controls, 
both at first and second periods of collection, and soluble 
CD-23 average concentrations of cases were lower when 
compared to the control group, but it did not reach sta-
tistical significance (Table 1). It was identified that the 
average concentration of CA-125 in the second collection 
allowed differentiating cases from controls with chronic 
pelvic pain (VAS >6), as well as the presence of deep 
dyspareunia. The differentiation of patients with intense 
chronic pelvic pain was also possible by CA-125/soluble 
CD-23 ratios, in the second collection (Table 1).
As for dysmenorrhea, we found that CA-125 average 
concentrations, in both collections, differentiated cases 
and controls when the complaint of infertility was ab-
sent and when the intensity of dysmenorrhea was high 
(VAS>6). This differentiation was also possible by bio-
markers ratio, in the second collection (Table 1). Re-
garding the presence of intestinal symptoms, cases and 
controls were differentiated by mean concentrations of 
CA-125, soluble CD-23 and CA-125/soluble CD-23 ra-
tios, also in the second collection (Table 2).
Concerning the lesions sites, it was observed that 
patients with endometriosis in all sites had higher 
CA-125 mean concentrations when compared to the con-
trol group, in both blood collections. The same was not 
observed in terms of average concentrations of soluble 
CD-23 (Table 3).
In advanced endometriosis (stage III or IV), the mean 
concentrations of CA-125, in both collections, were higher 
than in initial endometriosis (stage I or II) and in absence 
of endometriosis (Table 3). 
DISCUSSION 
In the present study, serum levels of CA-125 were higher 
in endometriosis patients when compared to the control 
group during both periods of the menstrual cycle evalu-
ated in the study. CA-125 concentration was higher in ad-
vanced stages of the disease in both samples and also in 
women with ovarian endometrioma. Concerning CD-23, 
no statistically significant differences were observed be-
tween groups.
CA-125 has been extensively studied and is considered 
a useful tool for clinical diagnosis of endometriosis2-4,13,14-16. 
High CD-23 concentrations have been observed in peri-
toneal fluid of women with endometriosis, suggesting the 
activation of B cells and a possible imbalance of humoral 
immune system in endometriosis6-8,17.
The decision to evaluate these markers in two stag-
es of the menstrual cycle was taken from studies that 
showed fluctuations in their concentrations, especially 
CA-125 during the menstrual cycle. Kafali et al.2 iden-
tified in women without endometriosis an increase 
of CA-125 concentration of 22% during menstruation, 
compared to other days of the cycle. Abrão et al.3 dem-
onstrated that during the first three days of the menstrual 
cycle, CA-125 concentrations were greater than the eighth 
and tenth day of the cycle.
Our study is the first one that evaluates both mark-
ers (CA-125 and CD-23) in patients with endometriosis. 
Although there is no direct relationship between markers 
CA-125 and CD-23, both participate in the pathophysiol-
ogy of endometriosis (proliferation and epithelial cellular 
inflammatory response/immune, respectively), justifying 
the assessment of these two markers in the same cohort 
of patients with and without endometriosis. Moreover, as 
panel markers evaluation has been previously published 
and still no satisfactory results were found, we thought 
that the association of these two markers could improve 
the auxiliary value of laboratory tests in predicting endo-
metriosis using a non-invasive diagnosis method.
In the present study, the average concentrations of CA-
125, higher in the case group than in the control group, 
reinforced the assertion that this marker may be useful as 
an auxiliary diagnosis and management of endometrio-
sis. Analyzing our results, we found that the average con-
centrations of CA-125 in the first collection (on the first, 
second or third day of the menstrual cycle) were always 
higher than in the second (eighth, ninth or tenth day of 
the cycle), both in cases and controls. Abrão et al.3,18 re-
ported the same results evaluated in serum samples ob-
tained during the menstrual cycle: on day 1, 2 or 3 of the 
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Table 1 – CA-125, sCD-23 and CA-125/sCD-23 levels in cases and control samples according to chronic pelvic pain, deep 
dyspareunia and dysmenorrhea
CA-125 sCD-23 CA-125/sCD-23
Samples Samples Samples
1st 2nd 1st 2nd 1st 2nd
Cases (n = 44) 51.98 ± 7.88 42.23 ± 5.66 42.85 ± 3.93 52.98 ± 10.58 1.64 ± 0.29 1.32 ± 0.22
Controls (n = 58) 29.19 ± 5.65 21.20 ± 2.78 54.47 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
p-value 0.018 0.001 0.132 0.697 0.048 0.017
Chronic pelvic pain            
Absent            
Case (n = 15) 47.01 ± 15.18 39.15 ± 1.8 47.43 ± 6.31 79.01 ± 28.48 0.98 ± 0.27 0.8 ± 0.22
Control (n = 28) 21.28 ± 3.0 19.09 ± 2.89 58.36 ± 11.33 54.37 ± 9.28 0.93 ± 0.25 0.76 ± 0.17
p-value 0.117 0.092 0.504 0.315 0.902 0.897
1 to 5            
Case (n = 11) 78.83 ± 19.40 54.58 ± 12.01 39.27 ± 10.21 34.75 ± 7.74 2.70 ± 0.8 2.04 ± 0.6
Control (n = 18) 38.82 ± 16.29 27.21 ± 7.62 59.28 ± 13.85 68.42 ± 19.61 1.07 ± 0.4 0.87 ± 0.28
p-value 0.132 0.053 0.314 0.125 0.053 0.058
6 to 10            
Case (n = 18) 39.72 ± 7.4 37.26 ± 7.69 41.23 ± 5.39 42.43 ± 7.86 1.54 ± 0.41 1.32 ± 0.33
Control (n = 12) 33.21 ± 10.28 17.10 ± 2.03 47.88 ± 10.67 51.26 ± 15.25 1.0 ± 0.28 0.53 ± 0.11
p-value 0.602 0.02 0.547 0.578 0.339 0.033
Deep dyspareunia            
Absent            
Case (n = 19) 54.74 ± 14.4 37.78 ± 8.2 48.22 ± 8.36 52.87 ± 8.82 1.27 ± 0.31 0.84 ± 0.14
Control (n = 30) 32.95 ± 8.56 21.81 ± 3.86 52.7 ± 8.99 54.86 ± 11.06 1.1 ± 0.25 0.78 ± 0.16
p-value 0.186 0.051 0.768 0.914 0.698 0.845
Present            
Case (n = 25) 41.8 ± 6.92 37.84 ± 5.83 37.17 ± 4.23 51.45 ± 17.65 1.86 ± 0.45 1.59 ± 0.36
Control (n = 18) 24.24 ± 4.47 21.28 ± 4.19 56.04 ± 10.75 59.59 ± 12.02 0.9 ± 0.26 0.75 ± 0.21
p-value 0.058 0.039 0.116 0.728 0.078 0.05
Dysmenorrhea            
Absent            
Case (n = 2) 135.55 ± 102.45 103.35 ± 69.85 41.2 ± 12.6 37.95 ± 9.05 2.79 ± 1.63 2.4 ± 1.26
Control (n = 18) 18.22 ± 2.52 16.25 ± 2.37 59.06 ± 14.09 52.26 ± 12.15 0.65 ± 0.16 0.38 ± 0.18
p-value 0.457 0.430 0.686 0.706 0.414 0.013
1 to 5            
Case (n = 5) 66.24 ± 39.15 35.34 ± 10.26 37.56 ± 6.29 39.62 ± 5.65 1.74 ± 0.91 0.89 ± 0.21
Control (n = 11) 59.76 ± 28.0 34.03 ± 13.02 53.7 ± 19.85 69.97 ± 22.23 1.51 ± 0.64 1.15 ± 0.48
p-value 0.897 0.950 0.538 0.212 0.842 0.726
6 to 10            
Case (n = 37) 45.54 ± 6.09 39.86 ± 5.54 43.66 ± 4.58 55.6 ± 12.53 1.57 ± 0.32 1.32 ± 0.26
Control (n = 29) 24.4 ± 2.3 19.41 ± 1.89 54.79 ± 9.13 57.19 ± 11.88 1.0 ± 0.25 0.63 ± 0.11
p-value 0.002 0.001 0.250 0.928 0.184 0.017
sCD-23, soluble CD-23; case, patients with endometriosis; control, patients without endometriosis; 1st, second or third day of the menstrual 
cycle; 2nd, eight, ninth or tenth day of the menstrual cycle.
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cycle and on day 8, 9 or 10 of the cycle and compared to 
stage of the disease. The advanced stage of the disease was 
also associated with high levels of CA-125. It could also 
be noted that the average concentrations of CA-125 dif-
ferentiate patients with stromal or well differentiated glan-
dular pattern from those without the disease only in the 
second sampling. This detailed analysis between concen-
trations of CA-125 and histological classification (stromal 
and glandular pattern) of pelvic endometriosis was not yet 
reported in the literature, which hindered the discussion 
of our findings. Also, in terms of stages of endometriosis, 
Mihalyi et al.19 reported differences in the concentration 
of CA-125 between cases and controls. It is noteworthy 
that these authors made this statement not only by using 
the CA-125 as complementary diagnostic biomarker, but 
they associated it with CA-19-9, IL-6, IL-8, high sensitivity 
C-reactive protein and tumor necrosis factor alpha, which 
seems to justify a greater sensitivity and specificity.
The average concentration of CA-125 allowed us to 
differentiate cases and controls in the second collec-
tion, in the presence of chronic pelvic pain and dys-
menorrheal, deep dyspareunia and intestinal symptoms 
as well as intense dysmenorrhea, in the first collection. 
These findings agreed with Barbosa et al.14, who reported 
Table 2 – CA-125, sCD-23 and CA-125/sCD-23 levels in cases and control samples according to infertility, urinary and 
intestinal symptoms
CA-125 sCD-23 CA-125/sCD-23
Samples Samples Samples
1st 2nd 1st 2nd 1st 2nd
Infertility            
Absent            
Case (n = 18) 45.67 ± 8.07 44.04 ± 7.51 43.8 ± 5.4 42.05 ± 5.75 1.4 ± 0.3 1.42 ± 0.3
Control (n = 30) 21.89 ± 2.11 17.93 ± 1.83 53.94 ± 10.09 54.73 ± 12.92 0.76 ± 0.15 0.64 ± .12
p-value 0.01 0.003 0.464 0.444 0.035 0.028
Present            
Case (n = 16) 46.1 ± 13.59 30.63 ± 7.64 40.38 ± 7.87 65.68 ± 27.41 1.55 ± 0.47 0.8 ± 0.17
Control (n = 17) 29.91 ± 8.15 21.1 ± 4.39 58.18 ± 12.97 66.94 ± 15.92 1.14 ± 0.39 0.74 ± 0.21
p-value 0.308 0.281 0.257 0.968 0.503 0.813
Never tried            
Case (n = 10) 72.78 ± 23.03 57.53 ± 16.61 45.1 ± 7.65 52.34 ± 13.54 20.21 ± 0.89 1.99 ± 0.74
Control (n = 11) 47.97 ± 26.65 30.26 ± 12.14 60.75 ± 18.37 53.54 ± 12.1 1.4 ± 0.64 1.04 ± 0.44
p-value 0.494 0.195 0.457 0.948 0.463 0.275
Cyclical intestinal symptoms            
Absent            
Case (n = 26) 56.71 ± 11.6 43.55 ± 7.66 47.56 ± 4.63 64.69 ± 17.03 1.39 ± 0.27 1.0 ± 0.16
Control (n = 35) 31.32 ± 8.65 23.87 ± 4.38 52.72 ± 9.33 47.50 ± 7.4 1.06 ± 0.24 0.93 ± 0.18
p-value 0.078 0.031 0.657 0.315 0.365 0.790
Present            
Case (n = 18) 45.16 ± 9.67 40.33 ± 8.57 36.04 ± 6.74 36.07 ± 6.88 2.0 ± 0.59 1.79 ± 0.48
Control (n = 23) 25.94 ± 5.65 17.14 ± 2.09 62.19 ± 11.52 74.19 ± 16.7 0.89 ± 0.29 0.46 ± 0.1
p-value 0.079 0.017 0.058 0.044 0.098 0.014
Cyclical urinary symptoms            
Absent            
Case (n = 44) 51.98 ± 7.88 42.23 ± 5.66 42.85 ± 3.93 52.98 ± 10.57 1.64 ± 0.29 1.32 ± 0.22
Control (n = 54) 30.19 ± 6.04 21.82 ± 2.97 54.12 ± 7.2 56.32 ± 8.34 1.02 ± 0.19 0.77 ± 0.13
p-value 0.031 0.002 0.173 0.802 0.065 0.034
sCD-23, soluble CD-23; case, patients with endometriosis; control, patients without endometriosis; 1st, second or third day of the menstrual 
cycle; 2nd, eight, ninth or tenth day of the menstrual cycle.
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that the presence of endometriotic lesions in symptom-
atic patients remained correlated with the expression of 
CA-125. Some authors suggest a correlation between lev-
els of CA-125 and the proliferative activity of epithelial 
cells in the lesions of endometriosis, because the disease 
is an inflammatory process associated with a change in 
immune cell functions20,21. For some patients, the gyne-
cologic examination may be normal as well as the symp-
toms may be absent, especially for those with superficial 
peritoneal disease22. By comparing patients without en-
dometriosis to those with endometriosis according to 
location of the ectopic implants, we concluded that the 
concentrations of CA-125 differed from the cases with 
ovarian endometriosis, which may be due to increased 
blood supply in that location, which would determine 
higher expression of the marker by epitheliocytes23.
Concerning soluble CD-23, there are few studies in 
the literature which correlate this marker with endo-
metriosis5-7,9. The comparison of average concentrations 
between cases and controls failed to distinguish the 
presence or absence of endometriosis. By analyzing the 
relationship between the symptoms of endometriosis and 
the concentrations of soluble CD-23, our results demon-
strated that, in the second collection, there was a signifi-
cant difference between cases and controls with intestinal 
symptoms.
The most relevant findings of our study were the con-
firmation of CA-125 as an auxiliary biological marker 
able to differentiate cases and controls. High CA-125 
levels were associated with clinical symptoms such as 
chronic pelvic pain, dysmenorrhea, deep dyspareunia, 
bowel symptoms, and contribute to the diagnosis of ovar-
CA-125 sCD-23 CA-125/sCD-23
Samples Samples Samples
1st 2nd 1st 2nd 1st 2nd
Localization            
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Ovarian (n = 9) 92.37 ± 26.88 64.86 ± 15.40 44.71 ± 5.3 46.31 ± 4.49 2.28 ± 0.63 1.5 ± 0.35
p-value 0.048 0.022 0.528 0.208 0.079 0.029
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Peritoneal (n = 20) 41.04 ± 8.52 32.09 ± 6.67 38.02 ± 6.77 59.04 ± 22.5 1.82 ± 0.53 1.48 ± 0.44
p-value 0.278 0.144 0.158 0.960 0.148 0.121
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Deep (n = 15) 42.34 ± 9.62 42.18 ± 9.77 48.18 ± 6.5 48.91 ± 8.83 1.02 ± 0.25 1.02 ± 0.23
p-value 0.283 0.055 0.572 0.582 0.939 0.306
p inter-localizations 0.03 0.092 0.518 0.874 0.256 0.628
ASRM classiﬁcation            
I-II (n = 19) 41.79 ± 8.94 32.59 ± 7.01 37.86 ± 7.13 60.16 ± 23.69 1.89 ± 0.55 1.52 ± .46
III-IV (n = 25) 59.73 ± 12.02 49.56 ± 8.24 46.64 ± 4.28 47.53 ± 5.47 1.46 ± 0.29 1.18 ± 0.19
p-value 0.265 0.14 0.274 0.56 0.468 0.446
Histological classiﬁcation            
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Stromal (n = 11) 55.22 ± 17.94 38.6 ± 7.09 46.72 ± 3.06 47.65 ± 3.36 1.21 ± 0.42 0.82 ± 0.14
Glandular well differentiated
(n = 27)
48.66 ± 7.84 41.22 ± 7.11 42.42 ± 6.18 43.73 ± 6.89 1.87 ± 0.42 1.48 ± 0.33
Glandular undifferentiated  
(n = 2)
35.9 ± 6.8 33.3 ± 10.0 39.05 ± 12.35 32.65 ± 10.85 1.08 ± 0.52 1.26 ± 0.72
Mixed glandular (n = 4) 73.58 ± 54.84 63.52 ± 37.98 37.02 ± 7.7 140.25 ± 109.12 1.57 ± 0.95 1.69 ± 0.84
p-value 0.807 0.692 0.926 0.07 0.78 0.627
sCD-23, soluble CD-23; control, patients without endometriosis; 1st, second or third day of the menstrual cycle; 2nd, eight, ninth or tenth day of the menstrual cycle.
Table 3 – CA-125, sCD-23 and CA-125/sCD-23 levels according to the site of the disease, ASRM staging and histolological 
classiﬁcation
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ian endometriosis. Moreover, it was possible to identify 
an association between the presence of intestinal symp-
toms and the average concentration of soluble CD-23 in 
the second collection.
Furthermore, one limitation of this study is the small 
number of samples in some of the groups evaluated. It 
may have contributed to the lack of association between 
the markers and some parameters analyzed in this study. 
A greater number of samples could contribute to a better 
accuracy of the parameters evaluated.
CONCLUSION
Our results do not invalidate the warning that for some 
patients physical examination may be normal as well as 
symptoms may be absent, especially for those with super-
ficial peritoneal disease. The ratio of the markers allows 
us to differentiate cases and controls with severe chronic 
pelvic pain (ranging from 6 to 10 – VAS), presence of 
severe dysmenorrhea, infertility absence, presence and 
absence of intestinal symptoms of urinary symptoms.
Thus, this study confirms that the noninvasive diag-
nosis of endometriosis remains a challenge despite the 
increase in diagnostic possibilities, represented by mea-
surement of CA-125 and soluble CD-23.
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